Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Common business sense
View:
Post by palinc2000 on Mar 24, 2022 7:26pm

Common business sense

Large pharmas and large bios are like hound dogs ....If they spot or scent a breakthru in oncology they  come fast and furious and will want to get a piece of the action ,,,,,,We can debate all we want on proof of concept but the real validation imo will be  if and when a third party shows up .....There is no way that THTX would close the door to some kind of collaboration even in the early part of Phase 1 b .....Big pharmas have very deep  pockets and are not risk adverse but they need to see some glimse of hope .....
Comment by Wino115 on Mar 25, 2022 12:07pm
I agree with you, but would just say that from what we have read in the scientific literature and from what Beleiveu and Marsolais have said, they are at the earliest stage of investigating the usefullness of sort1 as a targeting approach. They literally are the vanguard here.  We know there is the Sortina Bio group doing it, but approaching it from the view of sort1 being related to stem ...more  
Comment by palinc2000 on Mar 25, 2022 5:01pm
Maybe we should manage our expectations with respect to the certainty of initiating  Phase 1 b ......unless they can convince a big pharma to get involved
Comment by Biobob on Mar 25, 2022 5:06pm
Got an idea.. Sell the HIV frnachise for like 150M and buy a decent P2 coumpound and change the name and the adress.
Comment by PWIB123 on Mar 25, 2022 5:38pm
Let's just hope we have less investors who are scientists and more who are looking for any signal of value creation that incentivizes them to buy more shares before everything is completely understood.  Phew!  You all are tough. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities